Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results
-- Reports Neurology Franchise Annual Net Sales of $110.3 million , at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LAKE FOREST, Ill.
Toggle Summary Assertio Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results After The Close of Markets on Wednesday, March 6, 2019
LAKE FOREST, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019 , after the close of markets. Following the announcement, the Company will host a
Toggle Summary Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin
Company Anticipates Potential Market Launch by Early 2020 LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration ( FDA ) for its 505(b)(2)

Upcoming Events

There are currently no events to display.
Presentations

Recent SEC Filings

Filing date Description Form Filing Group View

8-K12B

8-K12B
Other
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com